Your browser doesn't support javascript.
loading
The viral approach to breast cancer immunotherapy.
Arab, Atefeh; Behravan, Nima; Razazn, Atefeh; Barati, Nastaran; Mosaffa, Fatemeh; Nicastro, Jessica; Slavcev, Roderick; Behravan, Javad.
Afiliación
  • Arab A; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Behravan N; Pharmaspring Inc, Richmond Hill, ON, Canada.
  • Razazn A; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Barati N; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mosaffa F; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Nicastro J; School of Pharmacy, University of Waterloo, Waterloo, ON, Canada.
  • Slavcev R; Waterloo Institute of Nanotechnology, University of Waterloo, Waterloo, ON, Canada.
  • Behravan J; School of Pharmacy, University of Waterloo, Waterloo, ON, Canada.
J Cell Physiol ; 234(2): 1257-1267, 2019 02.
Article en En | MEDLINE | ID: mdl-30146692
Despite years of intensive research, breast cancer remains the leading cause of death in women worldwide. New technologies including oncolytic virus therapies, virus, and phage display are among the most powerful and advanced methods that have emerged in recent years with potential applications in cancer prevention and treatment. Oncolytic virus therapy is an interesting strategy for cancer treatment. Presently, a number of viruses from different virus families are under laboratory and clinical investigation as oncolytic therapeutics. Oncolytic viruses (OVs) have been shown to be able to induce and initiate a systemic antitumor immune response. The possibility of application of a multimodal therapy using a combination of the OV therapy with immune checkpoint inhibitors and cancer antigen vaccination holds a great promise in the future of cancer immunotherapy. Display of immunologic peptides on bacterial viruses (bacteriophages) is also increasingly being considered as a new and strong cancer vaccine delivery strategy. In phage display immunotherapy, a peptide or protein antigen is presented by genetic fusions to the phage coat proteins, and the phage construct formulation acts as a protective or preventive vaccine against cancer. In our laboratory, we have recently tested a few peptides (E75, AE37, and GP2) derived from HER2/neu proto-oncogene as vaccine delivery modalities for the treatment of TUBO breast cancer xenograft tumors of BALB/c mice. Here, in this paper, we discuss the latest advancements in the applications of OVs and bacterial viruses display systems as new and advanced modalities in cancer immune therapeutics.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Genética / Vacunas contra el Cáncer / Virus Oncolíticos / Viroterapia Oncolítica / Antineoplásicos Inmunológicos / Vectores Genéticos / Inmunoterapia Límite: Animals / Female / Humans Idioma: En Revista: J Cell Physiol Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Genética / Vacunas contra el Cáncer / Virus Oncolíticos / Viroterapia Oncolítica / Antineoplásicos Inmunológicos / Vectores Genéticos / Inmunoterapia Límite: Animals / Female / Humans Idioma: En Revista: J Cell Physiol Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos